CLYM

Climb Bio (CLYM)

About Climb Bio (CLYM)

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Details

Daily high

$12.24

Daily low

$11.32

Price at open

$11.91

52 Week High

$12.48

52 Week Low

$1.13

Market cap

568.9M

Dividend yield

0.00%

Volume

1.1M

Avg. volume

953,669

P/E ratio

-13.45

Climb Bio News